4E-BP1, a critical component of the eukaryotic initiation factor 4E-binding protein (4E-BP) family, plays a pivotal role in regulating protein translation initiation, a fundamental process governing gene expression and cellular function. Functionally, 4E-BP1 acts as a negative regulator of translation by sequestering eukaryotic initiation factor 4E (eIF4E), a key component of the eIF4F complex responsible for cap-dependent translation initiation. In its inactive state, unphosphorylated 4E-BP1 binds tightly to eIF4E, thereby inhibiting its interaction with other initiation factors and ribosomes. This repression of translation initiation contributes to the maintenance of cellular homeostasis by controlling the expression of proteins involved in cell growth, proliferation, and survival.
Activation of 4E-BP1 occurs through phosphorylation-mediated mechanisms orchestrated by various kinases, prominently including the mammalian target of rapamycin complex 1 (mTORC1). Upon activation of mTORC1 in response to growth factors, nutrients, and cellular stress signals, downstream signaling cascades converge on 4E-BP1, leading to its phosphorylation at multiple serine and threonine residues. Phosphorylation of 4E-BP1 induces conformational changes that disrupt its binding to eIF4E, thus releasing eIF4E and allowing it to form the eIF4F complex with other initiation factors. This liberated eIF4F complex subsequently associates with the mRNA 5' cap structure, facilitating ribosome recruitment and translation initiation of mRNAs encoding proteins essential for cell growth and proliferation. Overall, elucidating the intricate mechanisms governing 4E-BP1 activation provides valuable insights into the regulation of protein synthesis and its implications in cellular physiology and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Activates AMPK, which can lead to 4E-BP1 activation via mTOR inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that indirectly can lead to 4E-BP1 activation via mTOR pathways. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Activates SIRT1, which can induce 4E-BP1 dephosphorylation and activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Blocks PI3K/Akt pathway, causing mTOR inhibition and subsequent 4E-BP1 activation. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
Activates AMPK, indirectly leading to mTOR inhibition and 4E-BP1 activation. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Directly inhibits mTOR, causing 4E-BP1 dephosphorylation and activation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
AKT inhibitor that can cause downstream mTOR inhibition and 4E-BP1 activation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor that can indirectly affect 4E-BP1 through cell-cycle regulation. | ||||||